Domov › Mikrocitni rak pljuč › Illinois
Klinične študije za Mikrocitni rak pljuč v Illinois
21 študij za Mikrocitni rak pljuč išče udeležence na lokacijah v Illinois.
Mesta v Illinois
Uradno besedilo študije (angleško)
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
- Hope and Healing Clinical Research, Hinsdale
- Hope and Healing Clinical Research, New Lenox
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07476287DESTINY-PANTUMOUR04
- Research Site, Decatur
Vključevanje udeležencevOpazovalna študija
Starost 18–130 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07124000A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- University of Chicago Medical Center /ID# 280149, Chicago
- OSF St. Francis Medical Center /ID# 279930, Peoria
- Springfield Clinic - First /ID# 281309, Springfield
- in še 1
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07365241Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Northwestern University Feinberg School of Medicine, Chicago
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT05983432A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Illinois Cancer Care, Peoria
- OSF St. Francis Medical Center, Peoria
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT07218146A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Illinois Cancer Care, Peoria
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT06646276A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- University of Chicago ( Site 1108), Chicago
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT06780137Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Illinois Cancer Specialists, Niles
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT06712355Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
- Northwestern, Chicago
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 28. avg. 2026 · NCT07057791Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
- City of Hope Chicago, Zion
Vključevanje udeležencevFaza 1
Starost 18–99 · Vsi spoli · Posodobljeno 21. avg. 2026 · NCT07531095A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- Illinois Cancer Specialists, Niles
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT06095505A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Rush MD Anderson Cancer Center, Chicago
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT06203210Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
- OSF Saint Francis Medical Center, Peoria
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 24. jul. 2026 · NCT06931626Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
- University of Illinois Chicago, Chicago
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 26. jun. 2026 · NCT06598306Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
- University of Illinois Chicago, Chicago
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 26. jun. 2026 · NCT07149363A Study of LY4175408 in Participants With Advanced Cancer
- The University of Chicago Medical Center (UCMC), Chicago
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 23. jun. 2026 · NCT07046923Tempus Small Cell Lung Cancer Observational Study (Sculptor)
- Illinois Cancer Care, Peoria
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 15. jun. 2026 · NCT05257551Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
- University of Illinois Cancer Center, Chicago
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 8. apr. 2026 · NCT04919382Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- Northwestern University, Chicago
- Northwestern Medicine Cancer Center Kishwaukee, DeKalb
- Northwestern Medicine Cancer Center Delnor, Geneva
- in še 7
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 30. mar. 2026 · NCT06769126Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
- Jesse Brown VA Medical Center, Chicago, IL, Chicago
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 11. mar. 2026 · NCT06681220Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
- University of Chicago Medicine, Chicago
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 4. mar. 2026 · NCT05068232Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.